Surmodics (SRDX) Receiving Somewhat Favorable Media Coverage, Analysis Finds
Media coverage about Surmodics (NASDAQ:SRDX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Surmodics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.2714884921573 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Surmodics (NASDAQ SRDX) traded up 0.16% during mid-day trading on Thursday, hitting $31.15. The stock had a trading volume of 20,607 shares. Surmodics has a 52 week low of $21.90 and a 52 week high of $32.80. The stock has a 50 day moving average price of $28.86 and a 200 day moving average price of $25.94. The firm has a market cap of $408.35 million, a PE ratio of 67.86 and a beta of 0.86.
Surmodics (NASDAQ:SRDX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.10. The company had revenue of $17.80 million for the quarter, compared to analyst estimates of $15.98 million. Surmodics had a return on equity of 7.28% and a net margin of 8.66%. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.37 EPS. Equities research analysts expect that Surmodics will post $0.31 EPS for the current fiscal year.
Several analysts have recently commented on SRDX shares. Aegis started coverage on Surmodics in a report on Tuesday, June 27th. They set a “buy” rating on the stock. BidaskClub cut Surmodics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Lake Street Capital started coverage on Surmodics in a report on Friday, July 14th. They set a “buy” rating and a $40.00 target price on the stock. Finally, ValuEngine cut Surmodics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $40.00.
In related news, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $27.28, for a total transaction of $27,280.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Gary R. Maharaj sold 5,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $25.75, for a total value of $128,750.00. Following the sale, the chief executive officer now owns 126,807 shares in the company, valued at approximately $3,265,280.25. The disclosure for this sale can be found here. Insiders have sold a total of 6,801 shares of company stock worth $178,338 in the last 90 days. 6.40% of the stock is currently owned by corporate insiders.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.